Preclinical efficacy of a favipiravir and nitazoxanide combination against Rift Valley Fever Virus

Sarah Chaput, Jean-Sélim Driouich, Boris Pastorino, Rayane Amaral, Géraldine Piorkowski, Pauline Darbon, Clément Diarra, Madeleine Giocanti, Nadège Néant, Gilda Grard, Stéphane Mély, Guillaume Lingas, Jérémie Guedj, Xavier de Lamballerie, Caroline Solas, Franck Touret, Antoine Nougairède

Open source

DOI: 10.1016/j.antiviral.2026.106402
Published: 2026-05
Container: Antiviral Research
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.antiviral.2026.106402,
  title = {Preclinical efficacy of a favipiravir and nitazoxanide combination against Rift Valley Fever Virus},
  author = {Sarah Chaput and Jean-Sélim Driouich and Boris Pastorino and Rayane Amaral and Géraldine Piorkowski and Pauline Darbon and Clément Diarra and Madeleine Giocanti and Nadège Néant and Gilda Grard and Stéphane Mély and Guillaume Lingas and Jérémie Guedj and Xavier de Lamballerie and Caroline Solas and Franck Touret and Antoine Nougairède},
  year = {2026},
  journal = {Antiviral Research},
  doi = {10.1016/j.antiviral.2026.106402},
  url = {https://doi.org/10.1016/j.antiviral.2026.106402}
}

RIS

TY  - JOUR
TI  - Preclinical efficacy of a favipiravir and nitazoxanide combination against Rift Valley Fever Virus
AU  - Sarah Chaput
AU  - Jean-Sélim Driouich
AU  - Boris Pastorino
AU  - Rayane Amaral
AU  - Géraldine Piorkowski
AU  - Pauline Darbon
AU  - Clément Diarra
AU  - Madeleine Giocanti
AU  - Nadège Néant
AU  - Gilda Grard
AU  - Stéphane Mély
AU  - Guillaume Lingas
AU  - Jérémie Guedj
AU  - Xavier de Lamballerie
AU  - Caroline Solas
AU  - Franck Touret
AU  - Antoine Nougairède
PY  - 2026
JO  - Antiviral Research
DO  - 10.1016/j.antiviral.2026.106402
UR  - https://doi.org/10.1016/j.antiviral.2026.106402
ER  -

APA

Chaput, S., Driouich, J., Pastorino, B., Amaral, R., Piorkowski, G., Darbon, P., Diarra, C., Giocanti, M., Néant, N., Grard, G., Mély, S., Lingas, G., Guedj, J., Lamballerie, X. D., Solas, C., Touret, F., & Nougairède, A. (2026). Preclinical efficacy of a favipiravir and nitazoxanide combination against Rift Valley Fever Virus. Antiviral Research. https://doi.org/10.1016/j.antiviral.2026.106402

Source records

crossref · retrieved 2026-09-27T05:06:33.636Z